• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [54 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nemolizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V]
2024 NIHR Health Technology Assessment programme Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
2024 Agency for Care Effectiveness (ACE) Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lebrikizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V]
2024 NIHR Health Technology Assessment programme Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT
2024 National Institute for Health and Care Excellence (NICE) Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over. NICE technology appraisal guidance 986
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis, adolescents 12 years and older) – Benefit assessment according to § 35a Social Code Book V]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tralokinumab (moderate-to-severe atopic dermatitis in adolescents) - Benefit assessment according to § 35a Social Code Book V]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V]
2023 NIHR Health Technology Assessment programme Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT
2022 NIHR Health Technology Assessment programme Assessing the efficacy and safety of methotrexate vs ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema in children Taskforce (TREAT) randomised controlled trial
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis) - Addendum to Commission A22-06]
2022 National Institute for Health and Care Excellence (NICE) Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 814
2021 Institute for Clinical and Economic Review (ICER) JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of crisaborole (Staquis®) for the treatment of atopic dermatitis
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tralokinumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2021 National Institute for Health and Care Excellence (NICE) Baricitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 681
2021 National Institute for Health and Care Excellence (NICE) Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal). NICE technology appraisal guidance 701
2020 Institute for Clinical Effectiveness and Health Policy (IECS) [Dupilumab in atopic dermatitis not adequately controlled with atopical therapy]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in adolescents) - Addendum to Commission A19-75]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V]
2018 NIHR Health Technology Assessment programme Adding emollient bath additives to standard eczema management for children with eczema: the BATHE RCT
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Synchronous balneo-phototherapy for atopic eczema - rapid report]
2018 National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 534
2017 NIHR Health Technology Assessment programme Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial
2017 NIHR Health Technology Assessment programme Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial
2016 NIHR Horizon Scanning Centre (NIHR HSC) Crisaborole for adults, adolescents and children with atopic dermatitis
2016 NIHR Horizon Scanning Centre (NIHR HSC) Dupilumab - atopic dermatitis: moderate to severe; inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable – second line
2011 NIHR Health Technology Assessment programme A multicentre randomised controlled trial and economic evaluation of ion-exchange water softeners for the treatment of eczema in children: the Softened Water Eczema Trial (SWET)
2011 The Netherlands Organisation for Health Research and Development (ZonMw) [Transmural care for hand eczema; a randomised controlled trial and cost-effectiveness evaluation]
2010 The Netherlands Organisation for Health Research and Development (ZonMw) [E-health in caring for patients with atopic dermatitis. An economic evaluation comparing usual care with Internet-guided monitoring and self-management training by a nurse practitioner]
2009 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Bioresonance for allergies, atopic dermatitis, non-organic gastrointestinal complaints, pain and rheumatic diseases
2008 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis]
2007 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis]
2006 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Therapy of moderate and severe psoriasis
2006 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Therapy of atopic eczema
2006 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Balneo-phototherapy]
2005 NIHR Health Technology Assessment programme The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation
2004 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Pimecrolimus (Elidel (R)) for atopic dermatitis
2004 NIHR Health Technology Assessment programme Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation
2004 West Midlands Health Technology Assessment Collaboration (WMHTAC) A systematic review of effectiveness and cost effectiveness of tacrolimus ointment for topical treatment of atopic dermatitis in adults and children
2004 Quality Improvement Scotland (NHS QIS ) Frequency of application of topical corticosteroids for atopic eczema
2004 Quality Improvement Scotland (NHS QIS ) Tacrolimus and pimecrolimus for atopic eczema
2004 National Institute for Health and Care Excellence (NICE) Tacrolimus and pimecrolimus for atopic eczema. NICE technology appraisal guidance 82
2004 National Institute for Health and Care Excellence (NICE) Frequency of application of topical corticosteroids for atopic eczema. NICE technology appraisal guidance 81
2001 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Tacrolimus ointment for the treatment of atopic dermatitis
2001 NIHR Horizon Scanning Centre (NIHR HSC) New products for atopic dermatitis - horizon scanning review
2000 NIHR Health Technology Assessment programme Systematic review of treatments for atopic eczema